openPR Logo
Press release

Drug-Loaded Oral Thin Films Market Inclinations & Development Status Highlighted for the Forecast Period between 2018 and 2026(segmented as: Antiulcer Antiasthamatics Antitussives Antihistamines Expectorants NSAID’S Others)

04-01-2019 08:55 AM CET | Advertising, Media Consulting, Marketing Research

Press release from: Fact.MR

Drug-Loaded Oral Thin Films Market Inclinations & Development

The oral route for drug administration takes up more than 50% of the available drug in the market. Drug-loaded oral thin films have composed drug quantity that is administered via mouth. The composition of drug-loaded oral thin films not only require API but need supporting biocompatible ingredients such as strip forming polymers, plasticizers, sweetening agents and saliva stimulating agents. Pharmaceutical companies are banking on oral agents to mark their product portfolio as oral consumables are more consumer friendly in terms of using it. By todays standard, drug-loaded oral thin films are a recognized and accepted technology for the total delivery of active pharmaceutical agents for OTC medications and are in the early phase of development for prescription drugs.

Drug-Loaded Oral Thin Films Market: Drivers and Restraints

There are clinical benefits associated with drug-loaded oral thin films that make it a diverse product category, they provide large surface area for dissolution of the required formulation. Rapid absorption rate summed with faster action and biocompatibility makes the drug-loaded oral thin films market more prominent one to cash on. Though there are clinical differences for the of use drug-loaded oral thin films as high dose of solution cannot be infused into the strip. Hence, examiners have confirmed that the concentration level of active substance can be improved up to 50%. The expensive packaging cost in developing drug-loaded oral thin films is also effecting the production and adoption of such product. These drug-loaded oral thin films are best suited for paediatric and geriatric patients who display a large patient pool and opportunity for other companies.

Major pharmaceutical companies and consumers alike have embraced drug-loaded oral thin films as a more sustainable and positive approach to other traditional over-the-counter medicine forms. Drug-loaded oral thin films offer accurate dosing in a safe and fast environment. Drug-loaded oral thin films have an effective format that is suitable and manageable, without the need of other supporting product.

Request Free Sample Report@ https://www.factmr.com/connectus/sample?flag=S&rep_id=2574

Drug-Loaded Oral Thin Films Market: Segmentation

Tentatively, the global drug-loaded oral thin films market can be segmented on the basis of drug type, distribution channel and geography.

Based on Drug Type, the global drug-loaded oral thin films market is segmented as:

Antiulcer
Antiasthamatics
Antitussives
Antihistamines
Expectorants
NSAID’S
Others
Based on Distribution Channel, the global drug-loaded oral thin films market is segmented as:

Hospital pharmacy
Retail pharmacy
E-commerce
Drug-Loaded Oral Thin Films Market: Overview

In North America more than 80 drug-loaded oral thin films brands have been launched since 2003. The drug-loaded oral thin films are marketed through all corners, be it a prescription drug or over the counter drug. The global market for drug-loaded oral thin films is expected to witness a continuous growth over a period due to technological differences. The market is expected to grow with growing incidence of HIVAN cases, but the drug-loaded oral thin films type could easily expect new technologies with better patient response.

Among the drug types, NSAIDs segment is expected to experience a robust growth with range of indications being covered by the formulation.

Drug-Loaded Oral Thin Films Market: Regional Outlook

Geographically, the global drug-loaded oral thin films market is segmented into North America, Latin America, Europe, Asia-Pacific excluding Japan (APEJ), Japan and the Middle East and Africa (MEA). North America is expected to be the dominant regional market for drug-loaded oral thin films owing to presence of key players and developed healthcare infrastructure. The drug-loaded oral thin films market in Asia Pacific excluding Japan is expected to grow at a significant CAGR due to expansion of offerings by the key providers and rise in generic medicines. Europe is expected to have a large share in the global drug-loaded oral thin films market throughout the forecast period due to its quality healthcare facilities and modern outlook for drug-loaded oral thin films use.

Request/View TOC@ https://www.factmr.com/connectus/sample?flag=T&rep_id=2574

Drug-Loaded Oral Thin Films Market: Key Players

The global market for drug-loaded oral thin films is highly fragmented. Examples of some of the key players operating in the global drug-loaded oral thin films market are Labtec, BioAlliance Pharma, MonoSol Rx, Hughes Medical Corp., Paladin Labs, ZIM Laboratories Limited, Indivior plc, Aquestive Therapeutics, Inc., Sumitomo Dainippon Pharma Co., Ltd., IntelGenx Corp., Pfizer, Inc., Novartis AG, Allergan plc, and NAL Pharma.

The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain. The report provides in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.

The report covers exhaustive analysis on:

Market Segments
Market Dynamics
Market Size
Supply & Demand
Current Trends/Issues/Challenges
Competition & Companies involved
Technology
Value Chain
Regional analysis includes

North America
US
Canada
Latin America
Brazil
Mexico
Argentina
Chile
Peru
Rest of LatAm
Europe
EU – 4 (Germany, France, Italy, Spain)
UK
BENELUX (Belgium, Netherlands, Luxemburg)
NORDIC (Norway, Denmark, Iceland, Sweden)
Eastern Europe (Poland, Ukraine, Czech Rep. etc.)
Rest of Europe
CIS & Russia
Japan
APEJ
Greater China
India
Korea
ASEAN Countries
Rest of APEJ
Middle East & Africa
GCC Countries
Turkey
Iran
Israel
South Africa
Rest of MEA
Report Highlights:

Detailed overview of parent market
Changing market dynamics in the industry
In-depth market segmentation
Historical, current and projected market size in terms of volume and value
Recent industry trends and developments
Competitive landscape
Strategies of key players and products offered
Potential and niche segments, geographical regions exhibiting promising growth
A neutral perspective on market performance
Must-have information for market players to sustain and enhance their market footprint.

Report Analysis@ https://www.factmr.com/report/2574/drug-loaded-oral-thin-films-market

About US
Fact.MR is a fast-growing market research firm that offers the most comprehensive suite of syndicated and customized market research reports. We believe transformative intelligence can educate and inspire businesses to make smarter decisions. We know the limitations of the one-size-fits-all approach; that’s why we publish multi-industry global, regional, and country-specific research reports.

Contact Us
Rohit Bhisey
Fact.MR
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Email: sales@factmr.com
Web: https://www.factmr.com/
Blog: https://factmrblog.com/
Read Industry News at - http://theguardiantribune.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Drug-Loaded Oral Thin Films Market Inclinations & Development Status Highlighted for the Forecast Period between 2018 and 2026(segmented as: Antiulcer Antiasthamatics Antitussives Antihistamines Expectorants NSAID’S Others) here

News-ID: 1680794 • Views:

More Releases from Fact.MR

Insulated Drinkware Market to Hit USD 2.57 Billion by 2033 | YETI, Thermos L.L.C., Hydro Flask Lead - Fact.MR
Insulated Drinkware Market to Hit USD 2.57 Billion by 2033 | YETI, Thermos L.L.C …
The global insulated drinkware market was valued at US$ 1.39 billion in 2023 and is forecasted to expand at a 6.3% CAGR over the next ten years. Worldwide sales of insulated drinkware are projected to reach US$ 2.57 billion by 2033-end.This robust growth is driven by increasing consumer awareness of sustainability, rising participation in outdoor activities, and the growing demand for reusable, eco-friendly products amid bans on single-use plastics. The market
Digital Twin Market is Growing at a CAGR of 34.3% d by 2033 | Key Players: ABB Ltd, ANSYS, Inc, AT&T Inc, AVEVA Group plc, Bentley Systems
Digital Twin Market is Growing at a CAGR of 34.3% d by 2033 | Key Players: ABB L …
Digital Twin Market is valued at USD 5 billion in 2023 and is projected to expand at a compound annual growth rate (CAGR) of 34.3%, reaching USD 95 billion by 2033. This explosive growth is driven by the increasing adoption of digital twins across industries to optimize operations, reduce costs, and enhance decision-making through virtual replicas of physical assets. Digital twins integrate IoT, AI, and data analytics to simulate real-world
Hemato Oncology Testing Market is Forecasted to Reach USD 23.64 Billion by 2033 | Fact.MR Report
09-02-2025 | Health & Medicine
Fact.MR
Hemato Oncology Testing Market is Forecasted to Reach USD 23.64 Billion by 2033 …
The global hemato oncology testing market is valued at USD 4.33 billion in 2023 and is projected to expand at a compound annual growth rate (CAGR) of 18.5%, reaching USD 23.64 billion by 2033. This rapid growth is driven by the increasing prevalence of blood-related cancers, such as lymphoma and leukemia, and advancements in diagnostic technologies like next-generation sequencing (NGS) and polymerase chain reaction (PCR). Hemato oncology testing plays a
Osseointegration Implants Market is Anticipated to Reach USD 6.85 Billion by 2035
09-02-2025 | Health & Medicine
Fact.MR
Osseointegration Implants Market is Anticipated to Reach USD 6.85 Billion by 203 …
Osseointegration Implants Market is poised for robust growth, with its valuation projected to rise from USD 3.17 billion in 2025 to USD 6.85 billion by 2035, reflecting a compound annual growth rate (CAGR) of 8%. This expansion is driven by the increasing prevalence of orthopedic and dental disorders, such as osteoarthritis, rheumatoid arthritis, and edentulism, which necessitate advanced implant solutions. Osseointegration implants, which fuse directly with bone to provide stable

All 5 Releases


More Releases for Drug

Injectable Drug Delivery Market Injectable Drug Delivery Market
Leading market research firm SkyQuest Technology Group recently released a study titled ' Injectable Drug Delivery Market Global Size, Share, Growth, Industry Trends, Opportunity and Forecast 2024-2031,' This study Injectable Drug Delivery report offers a thorough analysis of the market, as well as competitor and geographical analysis and a focus on the most recent technological developments. The research study on the Injectable Drug Delivery Market extensively demonstrates existing and upcoming
Global Advanced Drug Delivery Systems Market Size - By Product Type(Oral Drug De …
Market Overview and Report Coverage Advanced Drug Delivery Systems (ADDS) refer to innovative technologies designed to improve the administration and efficacy of therapeutics, enhancing the way medications are delivered to targeted areas within the body. These systems aim to optimize treatment outcomes by increasing the bioavailability, reducing side effects, and facilitating controlled drug release. Employing methods such as nanoparticles, liposomes, and implantable pumps, ADDS are revolutionizing personalized medicine and expanding therapeutic
Global Cancer Antibody Drug Conjugate Market Size, Drug Sales, Drug Dosage, Pric …
Global Cancer Antibody Drug Conjugate Market Size, Drug Sales, Drug Dosage, Price, and Clinical Trials Outlook 2029 Report Highlights: * Global Antibody Drug Conjugates Market Opportunity: > 40 Billion By 2029 * Global and Regional Antibody Drug Conjugate Market Insight * Approved Drugs Sales Insight Global and Regional, Yearly and Quarterly, 2019 -2023 * Approved Antibody Drug Conjugates - Availability, Dosage and Price Insight * Insight On Antibody Drug Conjugates In Clinical Trials: > 550
Alcohol Testing And Drug Testing Equipment Market 2025 Segmentation, Application …
Market Study Report, LLC, has compiled an exhaustive research study of the ‘Alcohol Testing And Drug Testing Equipment market’, detailing every single market driver and intricately analyzing the business vertical. This ‘Alcohol Testing And Drug Testing Equipment market’ study will aid in seeking out new business opportunities and fine-tuning existing marketing strategies through insights regarding SWOT analysis, market valuation, competitive spectrum, regional share, and revenue predictions. Alcohol abuse and drug
How much Diabetes Drug Market Impact Worldwide Medical Drug Industry?
Diabetes Drug Market From an insight perspective, the market report focuses on various levels of analyses — industry analysis, market rank analysis, and company profiles, which together comprise and discuss basic views on the competitive landscape, high-growth regions, and countries as well as their respective regulatory policies, Types ,Applications and opportunities in the market.  Diabetes is a metabolic disorder in which the body glucose level is elevated. There are two types of diabetes
Hepatitis Drug Market Hepatitis Drug Clinical Pipeline Report 2023
For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990 Report Table of Contents 1. Introduction to Hepatitis Disease 1.1 Prologue 1.1.1 History of Hepatitis 1.1.2 Causes of Hepatitis Disease 1.2 Types of Viruses which are Responsible for Hepatitis Disease 2. Global Prevalence of Hepatitis Infection 3. Available Drug Classes for Hepatitis Disease Treatment 3.1 Interferon Alfa Therapy 3.2 Protease Inhibitors Therapy 3.3 Polymerase